Immune Checkpoint Inhibitor–Induced Vitiligo-Like Depigmentation
This retrospective case series compares vitiligo resulting from immune checkpoint inhibitor (ICI) therapy vs preexisting vitiligo among patients receiving ICI treatment for cancer.
Authors
- Azael Freites‐Martínez (ORCID: https://orcid.org/0000-0002-3121-5667)
- Luca Rapparini (ORCID: https://orcid.org/0000-0002-4029-941X)
- Emily Avitan‐Hersh (ORCID: https://orcid.org/0000-0002-2154-7609)
- Vasiliki A. Nikolaou (ORCID: https://orcid.org/0000-0001-9340-9152)
- Zsuzsanna Lengyel (ORCID: https://orcid.org/0000-0001-9808-1651)
- Priscila Giavedoni (ORCID: https://orcid.org/0000-0002-1474-9261)
- Lukas Kraehenbuehl (ORCID: https://orcid.org/0000-0001-5411-5661)
- Bianca Maria Piraccini (ORCID: https://orcid.org/0000-0001-6537-9689)
- Dimitra Koumaki (ORCID: https://orcid.org/0000-0001-7074-2374)
- F. Dezoteux (ORCID: https://orcid.org/0000-0001-8930-1042)
- Stephano Cedirian (ORCID: https://orcid.org/0000-0002-9783-7864)
- Pietro Sollena (ORCID: https://orcid.org/0000-0002-1632-7791)
- Davide Fattore (ORCID: https://orcid.org/0000-0002-1925-1243)
- Aram Boada
- Yannick S. Elshot (ORCID: https://orcid.org/0000-0001-7148-2439)
- Ernesto Rossi (ORCID: https://orcid.org/0000-0002-6442-1707)
- L. Peuvrel (ORCID: https://orcid.org/0000-0002-4347-915X)
- Sònia Segura (ORCID: https://orcid.org/0000-0003-0653-1382)
- Julia Riganti (ORCID: https://orcid.org/0000-0001-5382-1863)
- Tatjana Radević
- Mariana Lopez Leon (ORCID: https://orcid.org/0000-0002-4599-7719)
- V. Sibaud (ORCID: https://orcid.org/0000-0003-2585-6633)
- Zoé Apalla (ORCID: https://orcid.org/0000-0002-9255-8196)
- Michela Valeria Rita Starace (ORCID: https://orcid.org/0000-0002-3981-1527)
- Ana‐Maria Forsea (ORCID: https://orcid.org/0000-0002-1007-7883)
- Ketty Peris (ORCID: https://orcid.org/0000-0002-5237-0463)
- Alessandro Pileri
- C. Carrera
- Chryssoula Papegeorgiou
- Nada Saffuri
Institutions
- Military Medical Academy (RS)
- Inserm (FR)
- Carol Davila University of Medicine and Pharmacy (RO)
- Technion – Israel Institute of Technology (IL)
- National and Kapodistrian University of Athens (GR)
- University of Zurich (CH)
- Aristotle University of Thessaloniki (GR)
- Université de Lille (FR)
- Rambam Health Care Campus (IL)
- Instituto de Salud Carlos III (ES)
- Hospital Italiano de Buenos Aires (AR)
- Agostino Gemelli University Polyclinic (IT)
- The Netherlands Cancer Institute (NL)
- Centre Hospitalier Universitaire de Lille (FR)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- University Hospital of Zurich (CH)
- Institut de Cancérologie de l'Ouest (FR)
- Centre for Biomedical Network Research on Rare Diseases (ES)
- Hospital Clínic de Barcelona (ES)
- Andreas Sygros Hospital (GR)
- Lille Inflammation Research International Center (FR)
- Parc de Salut (ES)
- University Hospital of Heraklion (GR)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Hospital Universitari Germans Trias i Pujol (ES)
- Hospital del Mar Research Institute (ES)
- Instituto de Investigación de Enfermedades Raras (ES)
- University of Naples Federico II (IT)
- Universitat de Barcelona (ES)
- University of Pecs (HU)
- University of Amsterdam (NL)
- Universidad Europea de Madrid (ES)
- University of Bologna (IT)
Publication Details
- Journal
- JAMA Dermatology
- Published
- 2024-12-23
- DOI
- https://doi.org/10.1001/jamadermatol.2024.5136
- Citations
- 8
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.87